<DOC>
	<DOCNO>NCT01624090</DOCNO>
	<brief_summary>Background : - Mithramycin drug first test cancer therapy 1960s . It act form cancer , never accept treatment . Research suggest may useful cancer chest , lung esophageal cancer mesothelioma . Researchers want see mithramycin use treat type cancer . Objectives : - To see mithramycin safe effective different chest cancer . Eligibility : - Individuals least 18 year age lung , esophagus , pleura , mediastinum cancer . Design : - Participants screen physical exam medical history . Blood urine sample collect . Imaging study tumor tissue sample use monitor cancer treatment . - Participants receive mithramycin every day 7 day , follow 7 day without treatment . Each 14-day round treatment call cycle . - Treatment monitor frequent blood test image study . - Participants continue take drug long side effect severe tumor respond treatment .</brief_summary>
	<brief_title>Mithramycin Lung , Esophagus , Other Chest Cancers</brief_title>
	<detailed_description>Background : Increasing evidence indicate activation stem cell gene expression common mechanism environmental carcinogen mediate initiation progression thoracic malignancy . Similar mechanism appear contribute extra-thoracic malignancy metastasize chest . Utilization pharmacologic agent , target gene regulatory network mediate stemness may novel strategy treatment neoplasms . Recent study perform Thoracic Epigenetics Laboratory , TGIB/NCI , demonstrate exposure condition potentially achievable clinical setting , mithramycin diminishes stem cell gene expression markedly inhibit growth lung esophageal cancer MPM cell vitro vivo . These find add recent preclinical study demonstrate impressive anti-tumor activity mithramycin epithelial malignancy sarcomas frequently metastasize thorax . Primary Objective : -To assess clinical response rate mithramycin administer 6 hour intravenous infusion patient malignancy involve lung , esophagus , pleura , mediastinum . Eligibility : - Patients measurable inoperable , histologically confirm primary lung esophageal carcinoma , thymic neoplasm , germ cell tumor , malignant pleural mesothelioma chest wall sarcoma , well patient gastric , colorectal renal cancer sarcomas metastatic thorax eligible . - Patients germline SNPs ABCB4 ABCB11 associate resistance mithramycin-induced hepatotoxicity . - Patients must refuse first-line standard therapy malignancy . - Patients must 18 year old ECOG performance status 0 2 , without evidence unstable decompensated myocardial disease . Patients must adequate pulmonary reserve evidence FEV1 DLCO equal great 30 % predict ; pCO ( 2 ) less 55 mm Hg pO ( 2 ) great 60 mm Hg room air ABG . - Patients must platelet count great 100,000 , ANC equal great 1500 without transfusion cytokine support , normal PT , adequate hepatic function evidence total bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST/ALT le equal 3 x ULN . Serum creatinine le 3 equal 1.6 mg/ml , creatinine clearance great 70 ml/min/1.73m^2 . Design : - Simon Optimal Two Stage Design Phase II Clinical Trials target objective response rate ( RECIST ) 30 % . - Patients stratify base location primary disease ( thoracic vs. extra-thoracic ) . - Patients receive 6 hour infusion mithramycin 30 -50 mcg/kg every day 7 day , every 21 day ( 1 cycle ) . Three cycle constitute one course therapy . Those patient tolerate 30 mcg/kg infusion first cycle receive subsequent cycle mithramycin dose 50 mcg/kg use infusion schedule . - Following course therapy , patient undergo restaging study . Patients exhibit objective response therapy stable disease RECIST criterion offer additional course therapy . - Patients exhibit disease progression remove study . - Biopsies index lesion obtain baseline day 8 second cycle therapy analysis molecular end-points . -Pharmacokinetics assess cycle 1 cycle 2 first course therapy .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Plicamycin</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis : Patients measurable inoperable , histologically confirm primary lung esophageal carcinoma , thymic neoplasm , germ cell tumor , malignant pleural mesothelioma chest wall sarcoma , well patient gastric , colorectal renal cancer sarcomas metastatic thorax eligible Histologic confirmation disease Laboratory Pathology , CCR , NCI , NIH . Disease amenable biopsy via percutaneous approach minimally invasive procedure thoracoscopy , bronchoscopy , laparoscopy , GI endoscopy Age &gt; 18 ECOG status 02 . Patients must refuse firstline standard chemotherapy inoperable malignancy . Patients must chemotherapy , biologic therapy , radiation therapy malignancy least 30 day prior treatment . Patients may receive localized radiation therapy nontarget lesion provide radiotherapy complete 14 day prior commence therapy , patient recover toxicity . At least 3 halflives must elapse since monoclonal antibody treatment . At least six week must elapse mitomycin C nitrosourea treatment . Patients must adequate organ marrow function define : ) Hematologic Coagulation Parameters : . Peripheral ANC great equal 1500/mm^3 ii . Platelets great equal 100,000/ mm^3 ( transfusion independent ) iii . Hemoglobin great equal 8 g/dL ( PRBC transfusion permit ) iv . PT/PTT within normal limit ( 11.6 15.2 / 25.3 37.3 sec ) b ) Hepatic Function i. Bilirubin ( total ) &lt; 1.5 time upper limit normal ( ULN ) ii . ALT ( SGPT ) less equal 3.0 time ULN iii . Albumin &gt; 2 g/dL c ) Renal Function i. Creatinine within normal institutional limit creatinine clearance great equal 60 mL/min/1.73 m^2 patient creatinine level institutional normal . ii . Normal ionized calcium , magnesium phosphorus ( oral supplementation ) Cardiac Function : Left ventricular ejection fraction ( EF ) &gt; 40 % Echocardiogram , MUGA , cardiac MR. Ability subject understand , willing sign inform consent . Female male patient ( relevant partner ) must willing practice birth control ( include abstinence ) two month treatment , childbearing potential sexual contact female childbearing potential . Patients must willing undergo 2 tumor biopsy EXCLUSION CRITERIA : Patients ABCB4 ABCB11 genotype associate mithramycinmediated hepatotoxicity . Clinically significant systemic illness ( e.g . serious active infection significant cardiac , pulmonary , hepatic organ dysfunction ) , judgment PI would compromise patient ability tolerate protocol therapy significantly increase risk complication Patients cerebral metastasis Patients follow pulmonary function abnormality exclude : FEV , &lt; 30 % predict ; DLCO , &lt; 30 % predict ( postbronchodilator ) ; pO2 &lt; 60 mm Hg pCO2 great equal 55 mm Hg room air arterial blood gas . Patients evidence active bleeding , intratumoral hemorrhage history bleeding diatheses , unless specifically occur isolate incident reversible chemotherapy induce thrombocytopenia Patients therapeutic anticoagulation . Note : prophylactic anticoagulation ( i.e . intralumenal heparin ) venous arterial access device allow Patients concurrently receive require follow agent , may increase risk mithramycin related toxicity , hemorrhage : Thrombolytic agent Aspirin salicylatecontaining product , may increase risk hemorrhage Dextran Dipyridamole Sulfinpyrazone Valproic acid Clopidogrel Lactating pregnant female ( due risk fetus newborn , lack test excretion breast milk ) Patients history HIV , HBV HCV due potentially increase risk mithramycin toxicity population Hypersensitivity mithramycin Patients opinion investigator may able comply safety monitoring requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 6, 2017</verification_date>
	<keyword>Cancer Stem Cell</keyword>
	<keyword>Thoracic Malignancies</keyword>
	<keyword>Mythramycin Treatment</keyword>
	<keyword>Lung Tumors</keyword>
	<keyword>Metastatic Lung Tumors</keyword>
</DOC>